Evidence map›Paper›PMID 38520727›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Neutrophil Targeting Platform Reduces Neutrophil Extracellular Traps for Improved Traumatic Brain Injury and Stroke Theranostics.

Qingchun Mu, Kai Yao, Madiha Zahra Syeda, Jinlong Wan, Qian Cheng, Zhen You, Rui Sun, Yufei Zhang, Huamiao Zhang, Yuting Lu and 10 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Engineered bacteria reprogram tumor microenvironmentActa pharmaceutica Sinica. B · 2026
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 3 countries.

Qingchun MuGaozhou People's Hospital, Maoming, 525200, China.
Kai YaoDepartment of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Madiha Zahra SyedaGaozhou People's Hospital, Maoming, 525200, China.
Jinlong WanGaozhou People's Hospital, Maoming, 525200, China.
Qian ChengBasic Medical College, Guilin Medical University, Guilin, 541199, China.
Zhen YouLiangzhu Laboratory, Zhejiang University, 1369 West Wenyi Road, Hangzhou, 311121, China.
Rui SunSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Yufei ZhangBasic Medical College, Guilin Medical University, Guilin, 541199, China.
Huamiao ZhangDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Yuting LuDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Zhicheng LuoGaozhou People's Hospital, Maoming, 525200, China.
Yang LiDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Fuyao LiuKey Laboratory for Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Huiping LiuDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Xinyu ZouGaozhou People's Hospital, Maoming, 525200, China.
Yanfen ZhuDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Kesong PengDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Chunming HuangGaozhou People's Hospital, Maoming, 525200, China.
Xiaoyuan ChenDepartments of Diagnostic Radiology, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, 119074, Singapore.ORCID 0000-0002-9622-0870
Longguang TangDepartment of Pharmacy, Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.ORCID 0000-0002-9517-1325
Zhejiang International Studies University · CNGaozhou People's Hospital · CNGuilin Medical University · CNZhejiang University · CNHarbin Medical University · CNNational University of Singapore · SGSouthern Medical University · CNSt. Michael's Hospital · CA

Funding

National Natural Science Foundation of China 32201127National Natural Science Foundation of China 82270113National Natural Science Foundation of China 82360366National University of Singapore NUHSRO/2020/133/Startup/08National University of Singapore NUHSRO/2021/034/TRP/09/NanomedicineNational University of Singapore NUHSRO/2023/008/NUSMed/TCE/LOANatural Science Foundation of Guangdong Province 2023A1515011386Natural Science Foundation of Guangdong Province 2023A1515012969Natural Science Foundation of Hainan Province 824RC546Scientific Research Project of Hainan General Hospital 2022MSXM06
6 · The paper itself

Abstract

Traumatic brain injuries (TBI) and stroke are major causes of morbidity and mortality in both developing and developed countries. The complex and heterogeneous pathophysiology of TBI and cerebral ischemia-reperfusion injury (CIRI), in addition to the blood-brain barrier (BBB) resistance, is a major barrier to the advancement of diagnostics and therapeutics. Clinical data showed that the severity of TBI and stroke is positively correlated with the number of neutrophils in peripheral blood and brain injury sites. Furthermore, neutrophil extracellular traps (NETs) released by neutrophils correlate with worse TBI and stroke outcomes by impairing revascularization and vascular remodeling. Therefore, targeting neutrophils to deliver NETs inhibitors to brain injury sites and reduce the formation of NETs can be an optimal strategy for TBI and stroke therapy. Herein, the study designs and synthesizes a reactive oxygen species (ROS)-responsive neutrophil-targeting delivery system loaded with peptidyl arginine deiminase 4 (PAD4) inhibitor, GSK484, to prevent the formation of NETs in brain injury sites, which significantly inhibited neuroinflammation and improved neurological deficits, and improved the survival rate of TBI and CIRI. This strategy may provide a groundwork for the development of targeted theranostics of TBI and stroke.

Indexed as

Brain Injuries, TraumaticDisease Models, AnimalExtracellular TrapsNeutrophilsStrokeAnimalsHumansMaleMiceProtein-Arginine Deiminase Type 4Reactive Oxygen SpeciesTheranostic NanomedicineProtein-Arginine Deiminase Type 4Reactive Oxygen Speciesneutrophilneutrophil extracellular traps (NETs)stroketheranosticstraumatic brain injury

Identifiers

PMID38520727
PMCPMC11151022
OpenAlexW4393110861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.